Ontology-based knowledge management of troglitazone-induced hepatotoxicity

Drug Discovery Today

Volumn 9, Issue 22, 2004, Pages 948-954

  Hug, Hubert ^a   Dannecker, Robert ^a   Schindler, Richard ^a   Bagatto, Dario ^a   Stephan, André ^a   Wess, Ralf Arno ^a   Gut, Joseph ^a  

^a TheraSTrat AG   (Switzerland)

Author keywords

ADRIS; Adverse drug reaction; drug development; Drug Discovery; drug safety; knowledge base; ontology; troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL] BENZAMIDE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ARYL SULFOTRANSFERASE; CERIVASTATIN; CISAPRIDE; KAVA; ORAL ANTIDIABETIC AGENT; PEMOLINE; SERTINDOLE; TROGLITAZONE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; GENETIC PREDISPOSITION; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER TOXICITY; MARKET; MEDICAL INFORMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SCIENCE;

EID: 7944233495     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03252-0     Document Type: Note

References (31)

1. Meyer U.A., Gut J. Genomics and the prediction of xenobiotic toxicity. Toxicology. 2002;181-182. 463-466
2. Lazarou J., et al. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279:1998;1200-1205
3. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 349:2003;474-485
4. National Audit Office (2003) Safety, quality, efficacy: regulating medicines in the UK. HC Session 2002-2003
5. Roses A.D. Pharmacogenetics. Hum. Mol. Genet. 10:2001;2261-2267
6. Evans W.E., McLeod H.L. Pharmacogenomics - drug disposition, drug targets and side effects. N. Engl. J. Med. 348:2003;538-549
7. Weinshilboum R. Inheritance and drug response. N. Engl. J. Med. 348:2003;529-537
8. Hug H., et al. ADRIS - The Adverse Drug Reactions Information Scheme. Pharmacogenetics. 13:2003;767-772
9. Misbin R.I. Troglitazone-associated hepatic failure. Ann. Intern. Med. 130:1999;330
10. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16:2003;679-687
11. Altman R.B., et al. Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics. 13:2003;3-5
12. Mattingly C.J., et al. Promoting comparative molecular studies in environmental health research: an overview of the comparative toxicogenomics database (CTD). Pharmacogenomics J. 4:2004;5-8
13. Bader G.D., et al. BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res. 31:2003;248-250
14. Ji Z.L., et al. Internet resources for proteins associated with drug therapeutic effects, adverse reactions and ADME. Drug Discov. Today. 8:2003;526-529
15. Honma W., et al. Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab. Dispos. 30:2002;944-949
16. Gibb C., et al. In vitro inhibition of phenolsulphotransferase by food and drink constituents. Biochem. Pharmacol. 36:1987;2325-2330
17. Honma W., et al. Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. Drug Metab. Dispos. 29:2001;274-281
18. Frank J., et al. Dietary (+)-catechin and BHT markedly increase alpha-tocopherol concentrations in rats by a tocopherol-omega-hydroxylase- independent mechanism. J. Nutr. 133:2003;3195-3199
19. Kassahun K., et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14:2001;62-70
20. Tettey J.N., et al. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14:2001;965-974
21. Funk C., et al. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate. Toxicology. 167:2001;83-98
22. Kumashiro R., et al. Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene. Hepatol. Res. 26:2003;337-342
23. Calkin A.C., et al. MK-767. Kyorin/Banyu/Merck. Curr. Opin. Investig. Drugs. 4:2003;444-448
24. Lehmann J.M., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:1995;12953-12956
25. Elstner E., et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8806-8811
26. Badawi A.F., Badr M.Z. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review). Int. J. Oncol. 20:2002;1109-1122
27. Burstein H.J., et al. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat. 79:2003;391-397
28. Yamamoto Y., et al. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 30:2002;155-160
29. Hewitt N.J., et al. Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes. Chem. Biol. Interact. 142:2002;73-82
30. Lipton P. Pharmacogenetics: the ethical issues. Pharmacogenomics J. 3:2003;14-16
31. Arakelian C. Corporate strategies for managing bioethical issues. Drug Discov. Today. 8:2003;386-388